Evaluation of reference dilution test methods for antimicrobial susceptibility testing of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis.
about
Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosisGenetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patientsDysfunctional CFTR alters the bactericidal activity of human macrophages against Pseudomonas aeruginosa.Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients.Accuracy of three automated systems (MicroScan WalkAway, VITEK, and VITEK 2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum beta-lactam agents.Compliance of clinical microbiology laboratories in the United States with current recommendations for processing respiratory tract specimens from patients with cystic fibrosisAntimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis.Management of refractory Pseudomonas aeruginosa infection in cystic fibrosisAccuracies of beta-lactam susceptibility test results for Pseudomonas aeruginosa with four automated systems (BD Phoenix, MicroScan WalkAway, Vitek, and Vitek 2).Cathelicidin peptides inhibit multiply antibiotic-resistant pathogens from patients with cystic fibrosis.Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis.Colistin susceptibility testing: evaluation of reliability for cystic fibrosis isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia.Validation of Vitek 2 nonfermenting gram-negative cards and Vitek 2 version 4.02 software for identification and antimicrobial susceptibility testing of nonfermenting gram-negative rods from patients with cystic fibrosis.Asiatic acid and corosolic acid enhance the susceptibility of Pseudomonas aeruginosa biofilms to tobramycin.
P2860
Q24550797-4F9C4BC5-2538-4DF3-9A00-38F562D8DC32Q29615301-E125814B-9B84-4C50-8D4A-8660C8D22D4AQ33916871-5C2C6470-5C58-413D-B1CF-FD8B9837A94AQ33966881-D25F10A1-A381-4F27-924C-453160F848B4Q34431957-7CF0A791-65A0-491F-8165-4044A7ED1676Q34568983-F10CCF20-7CCA-4BAA-818F-4AF5446E7ACBQ35005445-F791CAC7-799A-401A-873D-23A89FA7DF3BQ35026630-02C636CB-30D5-429B-A438-4E3EF43841E3Q35784407-B92CA3B5-CFEE-4A5C-97AC-8E5688E0F499Q39478540-20200A52-225C-4B24-875E-276B78125754Q39651481-5A81A440-A09F-401B-87A2-BA11F621A10DQ40953294-B7FC7CC7-B743-45BB-85A8-3DFF6D4526D2Q41976892-9DC3E7D2-771E-44C6-8438-209F01673EA5Q42045619-ED2A1CD7-663B-4912-BB15-6207591BAE04
P2860
Evaluation of reference dilution test methods for antimicrobial susceptibility testing of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Evaluation of reference diluti ...... patients with cystic fibrosis.
@ast
Evaluation of reference diluti ...... patients with cystic fibrosis.
@en
type
label
Evaluation of reference diluti ...... patients with cystic fibrosis.
@ast
Evaluation of reference diluti ...... patients with cystic fibrosis.
@en
prefLabel
Evaluation of reference diluti ...... patients with cystic fibrosis.
@ast
Evaluation of reference diluti ...... patients with cystic fibrosis.
@en
P2093
P2860
P1476
Evaluation of reference diluti ...... patients with cystic fibrosis.
@en
P2093
J Krzewinski
S A Marshall
S Whittier
P2860
P304
P407
P577
1999-09-01T00:00:00Z